Onkos Surgical
Designs and coordinates manufacturing of patient-specific 3D-printed surgical implants and virtual surgical planning platforms for musculoskeletal oncology and complex orthopedic reconstruction, with 1,000+ clinical cases delivered.
- CEO / Founder
- Patrick Treacy
- Team Size
- 51-200
- Stage
- Growth Stage
- Total Funding
- $125M
- Latest Round
- Series C
- Key Investors
- 1315 Capital; Canaan Partners; 3D Ventures; JSD Capital; SV Health Investors; Rocky Point Ventures
Technology & Products
Key Products
My3D (patient-specific pelvic implant platform, 510(k) cleared); ELEOS Limb Salvage System (with NanoCept antibacterial technology); NanoCept (antibacterial surface treatment for titanium implants); Virtual surgical planning and 3D anatomic modeling services; Patient-specific implant design and manufacturing coordination
Technological Advantage
Onkos Surgical's core advantage lies in regulatory validation (510(k) clearance for My3D pelvic implants) combined with demonstrated clinical adoption across 1,000+ cases, indicating both operational reliability and surgeon confidence. The company's proprietary workflow integrates advanced imaging, collaborative surgical planning, and patient-specific implant design—a system-level competitive advantage that is difficult to replicate without equivalent regulatory pedigree and clinical experience. The strategic partnership with 3D Systems (4-year agreement) secures manufacturing scale and technology access while Onkos retains design and workflow IP. NanoCept antibacterial technology adds product differentiation in infection prevention, a high-value outcome driver in orthopedic oncology. The moat is primarily regulatory and procedural (difficult to copy the integrated care pathway without FDA clearance and surgeon relationships) rather than patent-protected; long-term defensibility depends on continued market adoption, surgeon loyalty, and incremental clinical evidence of superior outcomes.
Differentiation
Value Proposition
Reduces surgical complexity and revision risk by delivering personalized reconstruction plans tailored to individual patient anatomy; enables surgeons to address cases with bone loss, tumor involvement, or revision history where standard implant approaches are inadequate. Integrated imaging-to-implant workflow accelerates surgical execution and leverages accumulated procedural knowledge from 1,000+ cases to refine design and planning protocols.
How They Differentiate
Onkos Surgical differentiates on regulatory clarity (510(k) clearance for My3D), focused vertical specialization (surgical oncology and musculoskeletal tumors vs. broad orthopedic portfolios of larger competitors), and integrated surgeon-driven planning workflow. Clinical traction (1,000+ cases) provides proof-of-concept that personalized implants drive adoption in high-complexity reconstruction. Competitors like NuVasive and Stryker offer broader portfolios but are not positioned specifically for surgical oncology or as comprehensively integrated design-to-implant services. restor3d is the closest direct competitor but lacks equivalent public clinical milestone documentation.
Market & Competition
Target Customers
Orthopedic surgeons, surgical oncologists, and hospital systems specializing in musculoskeletal tumor and complex bone reconstruction cases
Industry Verticals
Orthopedic surgery; Surgical oncology; Complex bone reconstruction; Musculoskeletal tumor management
Competitors
restor3d (patient-specific orthopedic implants and surgical planning); NuVasive (complex spine and orthopedic solutions); Stryker (diversified orthopedic portfolio including oncology); Zimmer Biomet (global orthopedic implant leader)
Growth & Milestones
Growth Metrics
1,000+ patient-specific My3D cases completed (milestone); 500+ NanoCept ELEOS cases; 106 employees (as of 2025); estimated $34.6M ARR (per third-party source)
Major Milestones
Founded 2015; FDA 510(k) clearance for ELEOS Limb Salvage System (2016); Series A financing and partnership with MicroPort Orthopedics; Series B funding ($17.6M, Canaan Partners lead, 2017); FDA 510(k) clearance for NanoCept antibacterial technology application (date unspecified); 500th NanoCept ELEOS case milestone; Series C funding ($15M, 1315 Capital lead, 2021); NanoCept Innovation Center opening (2024); 4-year partnership agreement with 3D Systems (2024); 1,000th My3D patient-specific pelvic implant case (2024/2025)